<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05116774</url>
  </required_header>
  <id_info>
    <org_study_id>BCX9930-202</org_study_id>
    <secondary_id>2020-004438-39</secondary_id>
    <nct_id>NCT05116774</nct_id>
  </id_info>
  <brief_title>BCX9930 for Treatment of PNH in Subjects With Inadequate Response to C5 Inhibitor Therapy</brief_title>
  <acronym>REDEEM-1</acronym>
  <official_title>A Randomized, Open-Label, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral BCX9930 Monotherapy for the Treatment of PNH in Subjects With Inadequate Response to C5 Inhibitor Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioCryst Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioCryst Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of BCX9930 monotherapy for&#xD;
      the treatment of PNH compared to continued C5 inhibitor therapy in adult PNH patients with&#xD;
      residual anemia despite treatment with a C5 inhibitor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, active comparator-controlled, open-label, parallel-group, 2-part study.&#xD;
      Parts 1 and 2 will be conducted in the same subjects.&#xD;
&#xD;
      Part 1 of the study is designed to evaluate the efficacy, safety, and tolerability of oral&#xD;
      BCX9930 monotherapy for 24 weeks versus continuing C5 inhibitor therapy in subjects with PNH&#xD;
      with inadequate response to their current C5 inhibitor therapy. Subjects will be randomized&#xD;
      to either discontinue C5 inhibitor therapy and start BCX9930 monotherapy or to continue C5&#xD;
      inhibitor therapy for the 24-week randomized treatment period. The primary efficacy and&#xD;
      safety analyses will be based on Part 1.&#xD;
&#xD;
      Part 2 of the study is designed to evaluate the long-term safety, tolerability, and&#xD;
      effectiveness of BCX9930 monotherapy when administered through Week 52. All subjects in Part&#xD;
      2 will receive BCX9930. Subjects who are randomized to BCX9930 monotherapy in Part 1 will&#xD;
      continue to receive BCX9930 in Part 2. Subjects who are randomized to C5 inhibitor therapy in&#xD;
      Part 1 will discontinue that therapy at the Week 24 visit and receive BCX9930 in Part 2.&#xD;
&#xD;
      The study is planned to enroll approximately 81 patients in various countries.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in hemoglobin</measure>
    <time_frame>mean of values at Weeks 12, 16, 20, and 24</time_frame>
    <description>Change from baseline in hemoglobin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who are transfusion-free</measure>
    <time_frame>from Day 14 to Week 24</time_frame>
    <description>Proportion of subjects who are transfusion-free</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of units of packed red blood cells transfused</measure>
    <time_frame>from Day 14 to Week 24</time_frame>
    <description>Number of units of packed red blood cells transfused</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale score</measure>
    <time_frame>mean of values at Weeks 12, 16, 20, and 24</time_frame>
    <description>Change from baseline in FACIT-Fatigue scale score; FACIT-Fatigue total scale score ranges from 0 to 52, with a higher score indicating less fatigue</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Paroxysmal Nocturnal Hemoglobinuria (PNH)</condition>
  <arm_group>
    <arm_group_label>BCX9930 monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 1, participants are randomized 2:1 to receive BCX9930 monotherapy or continue with current C5 inhibitor&#xD;
In Part 2, all subjects receive BCX9930 monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continued C5 inhibitor therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In Part 1, participants are randomized 2:1 to receive BCX9930 monotherapy or continue with current C5 inhibitor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCX9930</intervention_name>
    <description>Administered orally at a dose of 500 mg twice daily</description>
    <arm_group_label>BCX9930 monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eculizumab</intervention_name>
    <description>Administered by intravenous infusion per current dose regimen</description>
    <arm_group_label>Continued C5 inhibitor therapy</arm_group_label>
    <other_name>Soliris</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ravulizumab</intervention_name>
    <description>Administered as intravenous infusion per current dose regimen</description>
    <arm_group_label>Continued C5 inhibitor therapy</arm_group_label>
    <other_name>Ultomiris, ALXN1210, ravulizumab-cwvz</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, aged ≥ 18 years old&#xD;
&#xD;
          -  Body weight ≥ 40 kg&#xD;
&#xD;
          -  Documented diagnosis of PNH&#xD;
&#xD;
          -  Currently being treated with a stable C5 inhibitor regimen&#xD;
&#xD;
          -  Documentation of current vaccinations against Neisseria meningitidis and Streptococcus&#xD;
             pneumoniae or willing to start vaccination series&#xD;
&#xD;
          -  At screening: PNH clone size of ≥ 10% and hemoglobin ≤ 10.5 g/dL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known history of or existing diagnosis of hereditary complement deficiency&#xD;
&#xD;
          -  History of hematopoietic cell transplant or solid organ transplant or anticipated&#xD;
             candidate for transplantation&#xD;
&#xD;
          -  Myocardial infarction or cerebrovascular accident within 30 days prior to screening,&#xD;
             or current and uncontrolled clinically significant cardiovascular or cerebrovascular&#xD;
             condition&#xD;
&#xD;
          -  History of malignancy within 5 years prior to the screening visit&#xD;
&#xD;
          -  Active bacterial, viral, or fungal infection or any other serious infection within 14&#xD;
             days prior to screening&#xD;
&#xD;
          -  Treatment with anti-thymocyte globulin within 180 days prior to screening&#xD;
&#xD;
          -  Initiation of treatment with an erythrocyte or platelet growth factor, or danazol&#xD;
             within 28 days prior to screening&#xD;
&#xD;
          -  Receiving iron supplementation with an unstable dose in the 28 days prior to screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Austin G Kulasekararaj, MBBS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College Hospital NHS Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BioCryst Pharmaceuticals, Inc.</last_name>
    <phone>+1 (844) 273-2328</phone>
    <email>BCX9930clinicaltrials@biocryst.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 2, 2021</study_first_submitted>
  <study_first_submitted_qc>November 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 11, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BCX9930</keyword>
  <keyword>factor D inhibitor</keyword>
  <keyword>proximal complement inhibitor</keyword>
  <keyword>oral therapy</keyword>
  <keyword>paroxysmal nocturnal hemoglobinuria</keyword>
  <keyword>inadequate response to C5 inhibitor</keyword>
  <keyword>C5 inhibitor</keyword>
  <keyword>eculizumab</keyword>
  <keyword>ravulizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemoglobinuria</mesh_term>
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eculizumab</mesh_term>
    <mesh_term>Ravulizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

